● Recruiting
Phase I
Neurology
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
CC-97540, a novel oral immunomodulatory agent, is being evaluated for safety, tolerability, efficacy and pharmacokinetics across three distinct autoimmune neurological conditions: relapsing and progressive…
01 Jul 2026
NCT06220201